|
Tadeusz
Sebzda, Piotr Hanczyc, Department of Pathophysiology, Medical
University of Wroclaw, Poland
Yousif Saleh, Bernice F Akinpelumi, Department of Obstetrics
and Gynaecology, Medical University of Wroclaw, Poland
Maciej Siewinski, Faculty of Public Health, Medical
University of Wroclaw, Poland
Jerzy
Rudnicki, Clinical of Surgery and Oncology, Medical University
of Wroclaw, Poland
Correspondence to: Yousif Saleh, PhD, I Department of
Obstetrics and Gynaecology, Medical University of Wroclaw,
Chalubinskiego street 3; PL-50-368 Wroclaw, Poland.
saleh-yousif@mailcity.com
Telephone: +4871-7842413
Received: 2004-02-28
Accepted: 2004-05-13
Abstract
AIM:
To examine the effectiveness of human placental inhibitors, by
injecting vitamin E to rats with transplanted Morris-5123 hepatoma,
on the expression of cathepsins B and L in tumor, liver, lung and
blood sera after transplantation of Morris 5123 hepatoma.
METHODS:
Animals were divided into 10 groups receiving three different
concentrations of vitamin E and inhibitors along or in combination
and compared with negative control (healthy rats) and positive
control (tumor rats). Effectiveness of treatment was evaluated with
regard to survival time, tumor response and determination of the
activities of proteolytic enzymes and their inhibitors using
flurogenic substrates.
RESULTS:
Cathepsins B and L activities were elevated by 16-fold in comparison
with negative control tissues, and their endogenous inhibitor
activity decreased by 1.2-fold before treatment. In several cases,
tumors completely disappeared following vitamin E plus human
placental cyteine protease inhibitor (CPI) compared with controls.
The number of complete tumor responses was higher when 20 m/kg
vitamin E plus 400 mg of CPI was used, i.e. 7/10 rats survived more
than two mo. Cathepsins B and L were expressed significantly in
tumor, liver, lung tissues and sera in parallel to the increasing of
the endogenous inhibitor activity compared with the controls after
treatment (P<0.0001).
CONCLUSION:
The data indicate formation of metastasis significantly reduced in
treated rats, which might provide a therapeutic basis for
anti-cancer therapy.
ă 2005
The WJG Press and Elsevier Inc. All rights reserved.
Key
words: Morris-5123 hepatoma; Vitamin E; Human placenta cysteine
peptidase inhibitor; Cathepsin B; Cathepsin L
Sebzda
T, Hanczyc P, Saleh Y, Akinpelumi BF, Siewinski M, Rudniki J. Effect
of vitamin E and human placenta cysteine peptidase inhibitor on expression of cathepsins B and L in implanted hepatoma Morris
5123 tumor model in Wistar rats. World J Gastroenterol
2005; 11(4): 587-592
http://www.wjgnet.com/1007-9327/11/587.asp
INTRODUCTION
Lysosomal
cysteine protease (CP) plays an important role in the intracellular
protein turnover, proteolytic degradation of endocytosed proteins,
maturation cleavage of a number of precursor proteins[1]. Natural CP
inhibitors (CPI) include members of the cystatin superfamily (stefins,
i.e. family I cystatins, family II cystatins, and kininogens)[2].
Cystatins are distributed in different body fluids, suggesting a
regulatory and defensive role against host or exogenous CP. In human
blood plasma, CPI activities are represented by a2-macroglobulin,
low-molecular mass kininogen and a small amount of cystatin C[3].
Cathepsin B (cat B) is released from lysosomes during tumor necrosis
factor-alpha (TNF-a) cytotoxic signaling in hepatocytes and
contributes to cell death. These data implicate a sphingosine-cat B
interaction inducing lysosomal destabilization during TNF-a
cytotoxic signaling[4]. Isidoro et al.[5] indicate that the
lysosomal segregation of cathepsin D was less efficient and its
fractional secretion was higher in hepatoma-7777 cells than in
hepatocytes; in the second cell types, delivery to lysosomes and
processing of procathepsin D were differently sensitive to increases
in the vacuolar pH. Plasma and ascitic fluid of rats bearing the
Yoshida ascites hepatoma AH-130 were shown to contain high levels of
proteolytic enzymes cathepsins B and L, in their latent,
acidic-activated forms belonging to different classes active at
neutral and acidic pH[6]. Serum from patients with chronic liver
diseases (chronic hepatitis, cirrhosis, and hepatomas) showed
increased calciferin and acid protease in their serum compared with
that from normal subjects[7]. Recent evidence suggests that
cathepsin B (cat B) contributes to TNF-a induced apoptosis in
vitro. The data demonstrate that a cat B-mitochondrial apoptotic
pathway plays a pivotal role in TNF-alpha-induced hepatocyte
apoptosis and liver injury[8]. Since vitamin E increases the
antioxidant status of cells, its influence on cytotoxicity was
investigated, this effect was related to the concentration of
vitamin E in the cell culture medium. A vitamin E dose-related
response was also observed for the decreased toxicity of paracetamol
and caffeine[9]. Effects of low corn oil, high corn oil, and high
fish oil diets on altered hepatic foci development in female
Sprague-Dawley rats were investigated. These results suggest that
the type of dietary lipid is a more important determinant for gamma-glutamyl
ranspeptidase-positive foci development than the amount of dietary
lipid when rats consumed approximately the same amount of calories
in all the dietary groups, and the underlying mechanisms may be
partially ascribed to the antioxidant/oxidation status and
biotransformation/detoxification system of rats[10]. Inhibition of
liver cancer is therefore associated with induction of increased
microsomal enzyme activity[11]. It was found that vitamin E could
control the cellular formation of ras and myc oncogenes[12] and
raise in vivo the level of autogenic cysteine peptidases inhibitors[13]. The information suggests the possibility of its
application in adjuvant conventional oncological therapy. Vitamin E
could also reduce a cytostatic level in patients after conventional
chemotherapy[14]. The combined treatment of transplantable solid
mammary carcinoma in Wistar rats using photodynamic therapy and
proteinase inhibitor isolated from human placenta was done. The
results indicated that in several cases tumors were completely
disappeared following treatment HpD-PDT+CPI[15]. The aim of the
present study was to investigate the new therapy in the effect of
vitamin E and human placenta cysteine peptidase inhibitors on the
expression of cathepsins B and L in implanted hepatoma Morris 5123
tumor model in Wistar rats.
MATERIALS
AND METHODS
Animals
Male
and female Wistar rats weighing 180-200 g (age: approximately 2 mo)
were used. The rats were fed with normal diets during the
experimental period according to Nirwana et al.[16]. The food
composed of (% w/w): crude protein 20.0, crude fibre 5.0, crude fat
2.5, moisture 13.0, ash 7.0, calcium 0.7-1.4, total phosphorus
0.6-1.2, and nitrogen-free extract 51.0.
Human
placenta cysteine protease inhibitor (CPI)
The
inhibitors were purified and identified using affinity
chromatography on Sepharose 4B - papain, Sephadex G-75 gel
chromatography column, and ion exchange chromatography on a
DEAE-Sephacel column (Saleh et al. 2003)[17]. A highly
purified preparation of cysteine protease inhibitors was obtained
with a specific activity of 344.8 mEU/mg protein, and molecular
weight of 67 kDa (by SDS-PAGE). The solution was concentrated on
centricom (Amicon), lyophilized and stored at -20 °C until use.
The pure and sterile inhibitors were dissolved in physiological
saline and injected subcutaneously (sc.) at the doses of 200 mg and
400 mg per animal (in volume 0.1 mL).
Vitamin
E
Vitamin
E (400 mg/mL) solution was dissolved in corn oil and injected
subcutaneously (sc.) at the doses of 10 and 20 mg/kg per animal (in
volume 0.1 mL) obtained from Hasco, (Pharmaceutical Drugs
Production, Wroclaw, Poland).
Implantation
of tumor
Approximately
140 000 tumor cells of hepatoma Morris 5123 were implanted
intramuscularly in the left limb of the Wistar rats. Two wk after
implantation, the implanted tumor grew locally early in the course
of diseases and eventually invaded the surrounding organs causing
ascites and also metastasis in the lungs. Liver microangiography
demonstrated that the tumor received blood supply mainly from the
hepatic artery. The tumor was detected by histological examinations
of these tissues using conventional hematoxylin-eosin (HE) staining.
Experimental
design
The
experiment was carried out on 100 male and female Wistar rats, which
were divided into 10 groups: Group I:10 rats, which were given
normal diets without treatment during the experiment as control
negative (healthy); group 2 :10 rats with hepatoma Morris 5123,
which were given normal diets without treatment during the
experiment as control positive (tumor); groups 3 and 4 : tumor rats
were injected subcutaneously 10 and 20 mg/kg vitamin E in 0.1 mL
corn oil during the experiment groups 5 and 6 : tumor rats were
injected subcutaneously 200 and 400 mg human placenta purified
cysteine protease inhibitor (CPI) in 0.1 mL physiological solution
during the experiment groups 7 and 8 : tumor rats were injected
subcutaneously 200 mg CPI plus 10 and
20 mg/kg vitamin E groups 9 and 10 : tumor rats were injected
subcutaneously 400 mg CPI plus 10 and 20 mg/kg vitamin E. All
animals were injected for 10 d with human placenta purified cysteine
protease inhibitors (CPI). From the eleventh day the rats were
injected vitamin E for 30 d. After 8 wk, the experiment animals from
all groups were narcotized, decapitated and the tumor, lungs, liver,
and blood were taken and washed out of the blood with 0.9% NaCl and
homogenized in electric Potter’s
homogenizator according to the methods described by Malicka and Roth[18]. The activities of enzymes and histological examinations
were performed.
Determination
of cathepsin B and L activities
Cathepsin
B activity was measured according to Barrett et al.[19].
Fluorescence was measured in a luminescence spectrometer, Perkin
Elmer LS 50 B at 370 nmol/L excitation and 440 nmol/L emission
wavelengths using fluorescent substrate Z-Aeg-Arg-AMC for cathepsin
B and Z-Phe-Arg-AMC for cathepsin L. Fluorescence readings of the
sample assays were standardized with the reaction product 7-AMC
(7-amino-4-methylcoumarin)[20]. One mEU of activity was defined as
the quantity releasing 1 nmol/L of 7-AMC.
Inactivation
of a-macroglobulin
a-macroglobulin (a-M) was inactivated by incubation with 0.5 mol/L methylamine at 37
°C and pH 7.5 for 2 h in samples and activity of CPI37 was
determined[21]. Fifty uL of sample was preincubated with 50
mL
of water and 2.0 mL of 0.5 M
methylamine in 0.1 mol/L potassium phosphate pH 7.5 for 2 h at 37 °C. Fifty mL of 0.1% papain was then added and the samples were
incubated for 10 min at 37 °C. Then 50 mL of 0.66 mmol/L BANA
solution was added and the free b-naphtylamine was measured.
Inhibitory activity was determined[22].
CPI80, the total activity of cysteine proteinase inhibitors
was calculated. The procedure of assay was as follows. Fifty mL of
serum was preincubated with 50 mL of 0.03 mol/L HCl at 80
°C for
20 min, then with 2.0 mL of 0.5 mol/L methylamine at 37 °C for
2 h. Samples were centrifuged and incubated with 0.01% papain
solution, then the papain activity was determined and the activity
of inhibitors was calculated. △CPI: Difference between
CPI80 and
CPI37 was calculated, and the results were presented as complex
(latent) forms of inhibitors. △CPI =
CPI80 - CPI37. The amount of
vitamin E was determined by liquid chromatography, using a HPLC
apparatus (“Philips”) and a Pye Unicam PU 4020 UV detector. The
results were decoded with the use of Peak simple chromatography data
system program[23].
Protein
concentration
Total
protein concentration was determined by the Bradford method[24]
using bovine serum albumin as a standard.
Statistical
analysis
The
levels of variables in the cancer tissues and sera compared with the
control were analyzed statistically. The results of cathepsin B and
their inhibitor activity assays in the groups under study are given
as median and mean±SD. To compare data of tumor and control
tissues, Walloon’s rank test was used. P<0.05 was
considered statistically significant. The calculation of survival
probability was performed by the method developed by Kaplan and
Meier. Checking the significance of a relationship between survival
of rats and the levels of biochemical parameters was based on the
Log-rank test. The discrimination levels were calculated by a
computer program.
RESULTS
The
best results were obtained after combination of 20 mg of vitamin E
and a higher dose of CPI were used, i.e. 400 mg, in control groups.
In these cases the animals survived for longer than 8 wk. In
numerous cases the tumors were completely disappeared following CPI
and vitamin E application. Table 1 shows that the number of complete
tumor responses was higher when 400 mg of CPI was used plus 20 mg of
vitamin E, i.e. 7/10 rats, and survived more than two mo. Whereas
application of 10 mg of vitamin E and a lower dose of CPI (200 mg)
resulted in only 4/10 total tumor responses, and the rats survived
for about 26 d. The difference between these two groups was
significant (P≤0.0001). No complete tumor response was
achieved in all the other experimental groups. The vitamin E after
the last treatment with human placental CPI was injected
subcutaneously at the doses of 10 and 20 mg per animal for one
month. Cathepsin B and L activity was measured in all animals with
tumor homogenates and in untreated animal tissues (control). The
mean or median activity of cat B and L was much higher in tumor
homogenates in comparison with that in the negative control
homogenates and the differences were highly significant
(P≤0.0001) before treatment. While no significance was
observed in the activity of cathepsins B and L in tumor tissues
after the rats were given-high doses of inhibitors plus vitamin E
(P≤0.0005).
The total cat B and L activity was 88.5 mEU/mg
proteins in tumor tissue homogenates compared with 5.8 mEU/mg
protein in negative control tissue (P≤0.0005). Cathepsins B
and L activities were elevated 16-fold in comparison with negative
control tissue. Table 1 shows that the inhibitory activity of CPI
was significantly decreased from 10.5 mEU/mg protein in control
tissue to 8.5 mEU/mg protein in tumor tissue (P≤0.0005), thus
it decreased 1.2-fold in tumor tissues. The complex form △CPI was
also decreased from 14.2 mEU/mg protein in control tissue to 9.0 mEU/mg
protein in tumor tissue (P≤0.0005), with a decrease of
1.6-fold in tumor tissues.
Cathepsin B and L activity decreased in all vitamin E groups
by 1.0-1.3 fold, while in the rats obtained only CPI, the cathepsin
B and L activity decreased by 1.2-1.8 folds.
By the results from Table 1 also showed that the activities
of cathepsins B and L decreased by 5.8 and 11.8 fold after the rats
received 20 mg vitamin E plus 200 and 400 mg CPI in tumor tissues.
While the endogenous inhibitor activity was increased 7.4 and 10.5
folds respectively in the same groups, and the complex form △CPI
activity obtained in the same range to negative control group.
The results in Table 2 showed that the mean±SD of cat B and
L activities in the tissue homogenates were decreased from 68.9±23.6
mEU/mg protein and 28.8±10.4 mEU/mg protein before treatment to 8.4±2.5
mEU/mg protein and 3.8±1.6 mEU/mg protein, respectively, after the
rats received 20 mg vitamin E plus 400 mg CPI. Highly significant
differences were observed between the activities of cat B and L in
tissue homogenates before and after treatment with 20 mg vitamin E
plus 400 mg CPI (P≤0.0001), and this was similar to control
tissues. The activities of cat B and L were decreased by 8.2 and 7.6
fold, respectively. The endogenous inhibitors were increased from
9.0±2.3 mEU/mg protein before treatment to 79.4±22.5 mEU/mg
protein after the rats were administered 20 mg vitamin E plus 400 mg
CPI. This increased by about 9.0-fold. The activities of cat B and L
were also decreased significantly in liver and lung tissue
homogenates and in sera after treatment (P≤0.0001) in
comparison with negative control group. While the endogenous
inhibitors also increased significantly in comparison with negative
control group (P≤0.0001). The activities of cat B and L were
decreased 6.2 fold and 7.0 fold in liver tissues, and 9.3 fold and
6.0 fold in lung tissues, while 8.2-fold and 7.6-fold in sera,
respectively after treatment. The endogenous inhibitors were
increased 11.6, 10.2-folds, and 72.0-fold in liver, lung tissues and
in sera after treatment, respectively. No significance was observed
in cat B and L activities in tissue homogenates and in blood sera
after the rats obtained high doses of CPI plus vitamin E in
comparison to negative control group.
Table
1 Cathepsins B, L
and their inhibitor activities, survival time and the total cure
responses of hepatoma morris-5123 in Wistar rats before and after
treatment in comparison with negative control (median, mean±SD,
range)
|
Cathepsins
B, L (mEU/mg) |
Inhibitor (CPI80) (mEU/mg) |
Inhibitor
(CPI37) (mEU/mg) |
Complex
form (△CPI)
(mEU/mg) |
Survival
time (d) |
Cure
(yes/No) |
Value
(P) |
| Control
negative |
5.8 |
24.7 |
10.5 |
14.2 |
|
|
|
| (healthy) |
6.5±1.7 |
25.4±8.9 |
11.2±2.8 |
14.2±6.1 |
60.0 |
10/10 |
0.0005 |
|
(2.4-8.2) |
(12.6-40.7) |
(2.4-14.5) |
(10.2-26.2) |
|
|
|
| Control
positive |
88.5 |
17.5 |
8.5 |
9.0 |
09-12 |
|
|
| (Tumor) |
85.4±12.6 |
18.8±8.6 |
9.3±1.2 |
9.5±7.4 |
(10.5) |
2/10 |
0.0001 |
|
(10.5-123.9) |
(4.6-23.8) |
(1.4-12.5) |
(3.2-11.3) |
|
|
|
| Tumor+
10 mg |
80.5 |
28.7 |
16.4 |
12.3 |
12-26 |
|
|
| Vit
E |
81.8±20.6 |
29.5±12.0 |
17.0±5.5 |
12.5±6.5 |
(19.0) |
2/10 |
0.0005 |
|
(11.0-99.8) |
(6.7-35.7) |
(3.9-20.3) |
(2.8-15.4) |
|
|
|
| Tumor+20
mg |
78.7 |
35.6 |
20.3 |
15.3 |
15-30 |
|
|
| Vit
E |
79.4±20.4 |
36.6±15.0 |
21.5±4.6 |
15.1±
10.4 |
(22.5) |
3/10 |
0.0005 |
|
(10.7-97.4) |
(7.3-40.1) |
(4.2-22.0) |
(3.1-18.1) |
|
|
|
| Tumor+
200 μg |
56.5 |
46.3 |
35.8 |
10.5 |
16-30 |
|
|
| CPI |
57.4±15.1 |
47.7±20.0 |
37.0±17.6 |
10.7±2.4 |
(23.0) |
3/10 |
0.0001 |
|
(22.1-80.6) |
(12.3-52.9) |
(9.0-40.0) |
(3.3-12.9) |
|
|
|
| Tumor+
400 μg |
47.9 |
67.8 |
46.8 |
21.0 |
18-35 |
|
|
| CPI |
48.7±18.6 |
69.0±25.2 |
47.3±16.0 |
21.7±9.2 |
(21.5) |
4/10 |
0.0001 |
|
(23.2-68.9) |
(20.6-88.5) |
(14.4-60.1) |
(6.2-28.4) |
|
|
|
| Tumor+
10 mg Vit E |
41.8 |
71.8 |
52.3 |
18.5 |
27-38 |
|
|
| +Tumor+
200 μg CPI |
43.0±10.6 |
73.0±25.4 |
53.6±22.1 |
19.4±3.3 |
(32.5) |
4/10 |
0.0001 |
|
(12.0-46.7) |
22.7-82.8 |
(20.4-63.3) |
(2.3-11.5) |
|
|
|
| Tumor+
10 mg Vit E |
30.2 |
82.2 |
61.0 |
21.2 |
30-40 |
|
|
| +Tumor+
400 μg CPI |
31.6±12.0 |
83.5±29.8 |
62.4±25.5 |
21.1±4.3 |
(35.0) |
5/10 |
0.0001 |
|
(9.8-38.7) |
(26.9-93.7) |
(24.6-70.2) |
(2.3-23.5) |
|
|
|
| Tumor+
20 mg Vit E |
15.4 |
94.4 |
74.2 |
10.2 |
38-60 |
|
|
| +Tumor+
200 μg CPI |
16.5±2.8 |
95.8±35.4 |
75.6±33.1 |
10.2±2.3 |
(49.0) |
6/10 |
0.0001 |
|
(6.4-20.8) |
(37.8-112.7) |
(32.3-94.5) |
(5.5-18.2) |
|
|
|
| Tumor+
20 mg Vit E |
7.5 |
120.8 |
105.5 |
15.3 |
45-60 |
|
|
| +Tumor+
400 μg CPI |
8.4±1.8 |
122.0±43.6 |
107.0±39.2 |
15.0±4.4 |
(52.5) |
7/10 |
0.0001 |
|
(2.6-10.2) |
(45.8-135.5) |
(35.6-118.2) |
(10.2-17.3) |
|
|
|
The
significance of the differences in Medan values of tumor and control
tissues was calculated by Wilcoxon matched pair's signed-rank test.
Table 2 Activity values of cathepsins B and L and their
inhibitors in hepatoma Morris 5123 (median, mean±SD, range)
|
Before
treatment |
After
treatment |
| Cathepsin
B |
Cathepsin
L |
Endogenous
(CPI) |
Cathepsin
B |
Cathepsin
L |
Endogenous
(CPI) |
|
8.2 |
3.20 |
12.2 |
|
|
|
| Control
negative(Healthy) |
9.4±1.5 |
3.6±1.3 |
12.8±2.6 |
|
No
changes |
|
|
(1.5-12.7) |
(1.3-7.4) |
(3.4-15.7) |
|
|
|
|
67.6 |
28.4 |
8.5 |
7.6 |
3.4 |
78.5 |
| Control
positive (Tumor) |
68.9±23.6 |
28.8±10.4 |
9.0±2.3 |
8.4±2.5 |
3.8±1.6 |
79.4±22.5 |
|
(19.4-89.2) |
(6.4-35.2) |
(3.2-12.5) |
(3.4-10.2) |
(2.2-5.7) |
(23.9-96.5) |
|
46.6 |
17.2 |
4.3 |
6.3 |
2.2 |
63.2 |
| Liver |
47.9±20.5 |
18.8±8.6 |
5.6±1.1 |
7.8±2.9 |
2.7±1.0 |
64.8±25.7 |
|
(21.3-68.2) |
(6.4-25.8) |
(1.8-7.7) |
(2.9-8.6) |
(1.2-5.4) |
(27.9-74.3) |
|
26.7 |
10.8 |
3.6 |
2.6 |
1.5 |
45.8 |
| Lung |
27.9±18.3 |
12.0±4.2 |
4.6±0.9 |
2.9±0.5 |
2.0±0.4 |
47.1±21.5 |
|
(15.8-38.9) |
(6.4-19.4) |
(1.0-6.8) |
(0.8-3.7) |
(0.4-3.1) |
(23.7-56.0) |
|
12.6 |
8.0 |
1.2 |
1.5 |
1.6 |
114.8 |
| Sera |
13.9±4.2 |
9.3±2.8 |
1.6±0.1 |
3.7±0.9 |
1.7±0.6 |
115.3±45.4 |
|
(5.6-18.5) |
(2.9-11.3) |
(0.2-2.3) |
(0.04-3.2) |
(0.07-3.8) |
(44.7-123.9) |
| P |
|
≤0.0001 |
|
NS |
NS |
≤0.0001 |
The
significance of differences in median values of tumor and control
were calculated after and before treatment by Wilcoxon rank test.
NS, Not significant.
DISCUSSION
Cancer
cells are characterized with high motility, loss of function which
makes them unite with neighbouring cells, invasiveness, and lack of
sensibility to contact inhibition and general change of cell shape.
Adhesion and locomotion are the main capabilities of cells in tumor
growth and metastasis. Proteases are attractive targets for drug
development for therapeutic application. The use of novel inhibitors
in clinical practice is dependent not just on their specificity and
effectiveness, but mainly on the knowledge of their precise role in
mechanisms of the proteolysis system in the development of malignant
disease[25]. The combination of vitamin E with other cancer
chemopreventive agents appears to be a reasonable procedure[26].
Association of the balance between various proteases and their
inhibitors with cancer diseases has been widely studied to
understand the molecular mechanisms of development and metastasis of
tumors. It is an often presented result in literature that cysteine
peptidase activity in various malignant tumor tissues and body
fluids of cancer patients was altered compared to physiological
levels[27]. It has been widely noted that vitamin E showed numerous
beneficial effects through and beyond its antioxidative properties.
Consequently, vitamin E is expected to prevent degenerative diseases[28]. In the present study, we investigated the
effectiveness of vitamin E in combination with human placental
cysteine proteinase inhibitors (CPI). The results showed that the
number of complete tumor responses was higher when the rats obtained
400 mg of CPI plus 20 mg of vitamin E, i.e. 7/10 rats. Whereas
application of 10 mg vitamin E and a lower dose of CPI (200 mg)
resulted in only 4/10 total tumor responses. The present study could
be explained in such a way that CPI damaged the cancer cells. The
number of total (complete) tumor responses was distinctly higher
after application of 400 mg CPI than 200
mg CPI. This indicated that
in the same conditions of vitamin E, the efficacy of treatment of
CPI was dose-dependent. Saleh et al.[15] indicated that in
several cases tumors completely disappeared following the treatment
with mammary carcinomas using HpD-PDT+CPI. Another independent
research direction was the therapeutic indications of vitamin E in
carcinogenesis processes[29].
The data obtained in this work involving hepatoma morris-5123
carcinoma in model Wistar rats were compared with those in
non-cancerous tissues as a negative control before and after
treatment. High activity of cathepsins B and L with a noteworthy
simultaneous decrease of the activity of endogenous cysteine
protease inhibitors was observed before treatment in tumor, liver,
lung tissues and in sera in comparison with negative control tissue
homogenates. Cathepsin B and L activities were elevated 16-fold as
against negative control tissues before treatment. The endogenous
inhibitor activity also decreased 1.2 fold, and the complex form △CPI decreased 1.6-fold in tumor tissues. They provided further
evidence for the alteration of the protease/inhibitor balance that
occurred during the process of tumor cell invasion. Since the level
of proteinases and inhibitors in extracellular fluids may reflect
not only their local expression in tumors but also the systemic
response to the disease, the mechanisms of the alteration of
protease/inhibitor balance are not solved. The highly significant
difference was observed between the levels of cathepsins and/or
their precursor in malignant tumor tissue before treatment. Tumor
tissue activity of cat B and L might be related to the severity of
cancer disease and there are some prognostic aspects of such studies
since it previously showned-that patients with higher content or
increased proteolysis activities of cat B and its precursor in
tissue homogenates of breast, ovarian and gastric cancer had
significantly higher risk of recurrence or death than the cases with
low content of the enzyme[30-32].
After the rats were injected with 20 mg vitamin E plus 400 mg
CPI, the cat B and L were expressed significantly in tumor, liver,
lung tissues and in sera in parallel to the increasing of the
endogenous inhibitor activity (P≤0.0001). The rats survived
for a longer period and they returned to normal life without any
stress. Nyandieka et al.[33] suggested that vitamins could
inhibit liver cancer by inducing hepatic microsomal enzymes that
metabolise aflatoxins to non-carcinogenic products.
Welss et al.[34] demonstrated that hurpin was an
intracellular, differentially spliced member of the serpin
superfamily that has been linked to differentiation and apoptosis of
human keratinocytes. It can be transiently down regulated by UV
light and overexpressed in psoriatic skin lesions. It is a potent
and selective inhibitor of the archetypal lysosomal cysteine
proteinase cathepsin L.
Sakamoto et al.[13]. Suggested that vitamin E
administration could stimulate macrophages to szynthesize
interleukin 1 and then, acted on fibroblasts and lymphocytes, thus
raising the interleukin 6 levels. As a final effect it could
increase T-kininogen level, which is one of the fundamental cysteine
peptidase inhibitors, thus suppressing the activity of the enzymes
catalyzing processes accompanied neoplastic progress. The results
showed that the increased amounts of kininogen might react with
cysteine peptidases. Tandon et al.[29] also supposed that as
an effect of vitamin E activity, an inhibition of the “enzymatic
metabolism cascade” took place. Moreover, vitamin E removing toxic
cytostatics and their metabolites from the organs could facilitate
its regeneration after harmful action of the substances. In
conclusion, human placental inhibitors used in combination with high
doses of vitamin E can significantly reduce the formation of tumors
in rats, and provide a therapeutic basis for anti-cancer therapy.
REFERENCES
1
Siewiński M. Autologous cysteine peptidase inhibitors as
potential anticancer drugs. Anti Cancer Drugs 1993; 4: 97-98
2
Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more
than scavengers. Biochim Biophys Acta
2000; 1477: 98-111
3
Wiederanders B. The function of propeptide domains of
cysteine proteinases. Adv Exp Med Biol 2000; 477: 261-270
4
Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor
necrosis factor-alpha-associated lysosomal permeabilization
is
cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol 2002;
283: G947-956
5 Isidoro C, Demoz M, De Stefanis D,
Mainferme F, Wattiaux R, Baccino FM. Altered intracellular
processing and enhanced
secretion of procathepsin D in a highly
deviated rat hepatoma. Int J Cancer 1995; 60: 61-64
6 Isidoro C, Demoz M, De Stefanis D,
Baccino FM, Bonelli G. High levels of proteolytic enzymes in the
ascitic fluid and
plasma of ratsbearing the Yoshida AH-130
hepatoma. Invasion Metastasis 1995; 15: 116-124
7 Terayama H, Shimizu N, Fukuzumi R.
Calciferin and cathepsin D-like acid protease in serum in acute and
chronic liver
injuries in rats and humans. Clin Chem 1989;
35: 2202-2206
8 Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ.
Cathepsin B knockout mice are resistant to tumor necrosis
factor-alpha-mediated hepatocyte apoptosis and liver injury:
implications for therapeutic applications. Am J Pathol
2001;
159: 2045-2054
9 Dierickx PJ, Smit C, Scheers EM.
Cytotoxicity of the MEIC reference chemicals in
antioxidant-enriched, rat
hepatoma-derived Fa32 cells. Altern Lab
Anim 2001; 29: 217-223
10 Lii CK, Ou CC, Liu KL, Liu JY, Lin WL, Chen HW.
Suppression of altered hepatic foci development by a high fish oil
diet
compared with a high corn oil diet in rats.
Nutr Cancer
2000; 38: 50-59
11 Nyandieka HS, Wakhisi J, Kilonzo M. Inhibition of
AFB1-induced liver cancer and induction of increased microsomal
enzyme activity by dietary constituents.
East Afr Med J 1989;
66: 796-803
12 Prasad KN, Cohrs RJ, Sharma OK. Decreased
expression of c-myc and H-ras oncogens in vitamin E
succinate induced
morphologically differentiated murine B-16
melanoma cells in culture. Biochem Cell Biol 1990; 68:
1250-1255
13 Sakamoto W, Yoshikawa K, Shinadoh M, Ameyama A, Handa O, Saeki T, Nagasava S, Koyama J, Ogihara T,
Mino M.
In vivo effect of vitamin E on peritoneal macrophages
and T-kininogen level rats. Int J Vitam Nutr Res
1989;
59: 131-139
14 Ells GW, Chisholm KA, Simmons VA, Horrobin DF.
Vitamin E blocks the cytotoxic effect of gamma-linolenic acid when
administered as late as the time of onset of cell death-insight into
the mechanism of fatty acid induced cytotoxicity.
Cancer Lett
1996; 98: 207-211
15 Saleh Y, Ziółkowski
P, Siewiński M. The combined treatment of transplantable solid
mammary carcinona in wistar rats
by use of photodynamic therapy and
cysteine proteinase inhibitor. In Vivo 2001; 15: 351–358
16 Nirwana I, Jamaludin M, Khalid BAK, Merican Z,
Baharom S. Serium lipids of castrated rats given hormonal
replacement
and fed diets with added soybean oil or palm oil.
Asia
Pacific J Clin Nutr 1995; 4: 244-248
17 Saleh Y, Siewinski M, Sebzda T, Jelen M, Ziolkowski
P, Gutowicz J, Grybos M, Pawelec M. Inhibition of cathepsin B
activity in human breast cancer tissue by cysteine peptidase
inhibitor isolated from human placenta:
immunohistochemical and
biochemical studies. Folia Histochem Cytobiol 2003; 41:
161-167
18 Malicka-Błaszkiewicz
M, Nowak D, Hańczycowa H, Ponikowski P, Sebzda T. Actin content and
polimerysation in tumor,
liver and serum of hepatoma Morris 5123
tumor bearing rats. Mat Med Pol 1995; 25: 115-118
19 Barrett AJ. Fluorimetric assays for cathepsin B and
cathepsin H with methylcoumarylamide substrates. Biochem J
1980; 187: 909–912
20 Barrett AJ, Kirschke H. Cathepsin B, Cathepsin H,
and cathepsin L. Methods Enzymol 1981; 80(Pt c): 535–561
21 Heidtmann HH, Salge U, Abrahamson M, Bencina M,
Kasteliv L, Kopitar-Jerala N, Turk V, Lah TT. Cathepsin B and
cysteine proteinase inhibitors in human lung cancer cell lines.
Clin
Exp Metastasis 1997; 15: 368–381
22 Siewiński M, Kręcicki T, Jarmulowicz J, Berdowska
I. Cysteine proteinase inhibitors in serum of patients with head and
neck tumors.
Diagn Oncol 1993; 2: 323-326
23 Nilsson B, Johansson B, Johansson L, Holmberg L.
Determination of plasma a-tocopherol by high - performance liuid
chromatography.
J Chromatography 1978; 145: 169-172
24 Bradford M. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle
of protein-dye binding.
Anal Biochem 1976; 72:
248–254
25 Duffy MJ. The role of proteolytic enzymes in cancer
invasion and metastasis. Clin
Exp Metastasis 1992; 10: 145-155
26 Lah TT, Kos J. Cysteine proteinases in cancer
progression and their clinical relevance for prognosis. Biol Chem
1998; 379: 125–130
27 Lockwood K, Moesgaard S, Hanioka T, Folkers K.
Apparent partial remission of breast cancer in ‘high risk’
patients
supplemented with nutritional antioxidants, essential fatty
acids and coenzyme Q10. Mol Aspects Med
1994; 15(Suppl):
S231-240
28 Battisti C, Formichi P, Tripodi S, Vindigni C,
Roviello F, Federico A. Vitamin E serum levels and gastric cancer:
results
from and cohort of patients in Tuscany, Italy.
Cancer
Lett 2000; 151: 15-18
29 Tandon SK, Singh S. Influence of vitamin E on
preventive or therapeutic effect of MFA and DTPA in cadmium
toxicity.
Biomed Environ Sci 1995; 8: 59-64
30 Saleh Y, Siewinski M, Kielan W, Ziolkowski P,
Grybos M, Rybka J. Regulation of cathepsin B and L expression in
vitro in
gastric cancer tissues by egg
cystatin. J Exp Ther
Oncol 2003; 3: 319-324
31 Siewinski M, Saleh Y, Popiela A, Ziolkowski P,
Jelen M, Grybos M. Expression of high molecular weight cysteine
proteinase inhibitor in ovarian cancer tissues: regulation of
cathepsin B expression by placental CPI. Biol Chem
2003; 384:
1103-1107
32 Saleh Y, Siewinski M, Sebzda T, Grybos M, Pawelec
M, Janocha A. Effects of combined in vivo treatment of
transplantable solid mammary carcinoma in wistar rats using vitamin
E and cysteine peptidase inhibitors from human
placenta.
J Exp
Ther Oncol 2003; 3: 95-102
33 Nyandieka HS, Wakhisi J. The impact of vitamins A, C, E,
and selenium compound on prevention of liver cancer in rats.
East
Afr Med J 1993; 70: 151-158
34
Welss T, Sun J, Irving JA, Blum R, Smith AI, Whisstock JC,
Pike RN, von Mikecz A, Ruzicka T, Bird PI, Abts HF. Hurpin is
a
selective inhibitor of lysosomal cathepsin L and
protectskeratinocytes from ultraviolet-induced apoptosis. Biochemistry
2003; 42: 7381-7389
Assistant
Editor Guo SY Edited by
Wang XL Proofread by Ma
JY
| |